N-terminus and C-terminus

N-terminus peptide meaning: a peptide has two chemically different ends—the N-terminus is the start, with a free amino group, and the C-terminus is the finish, with a free carboxyl group. Sequences are written N to C, and either end can be chemically capped to change stability or activity.

What do N-terminal vs C-terminal mean?

N-terminal means “at or near the N-terminus,” while C-terminal means “at or near the C-terminus.” The first amino acid is residue 1; the last is the C-terminal residue. In plain English, N-terminal vs C-terminal is start versus finish—not two kinds of peptide.

N-terminus peptide meaning is about direction, not a separate peptide class.

The letters come from the chemistry. “N” points to nitrogen in the free amino group. “C” points to carbon in the free carboxyl group. That is the basic C-terminus meaning behind phrases such as “C-terminal fragment.”

“Terminus” is the noun for the end itself. “Terminal” is the adjective for something located there: an N-terminal amino acid, a C-terminal modification, or an N-terminal fragment. The paired terms belong together because naming only one end leaves the reader with half a map.

The labels can also describe regions of a larger protein. An “N-terminal fragment” comes from the protein’s starting region; a “C-terminal fragment” comes from its finishing region. Once cut free, that fragment is also a peptide with its own N-terminus and C-terminus. Context tells you whether the writer means an end, a nearby region, or a piece taken from that region.

Why are peptide sequences written N to C?

Peptide sequences are written from the N-terminus on the left to the C-terminus on the right. The convention gives every amino-acid sequence one reading direction. Reverse the letters and the result is a different peptide, even though the amino-acid inventory stays the same.

This is why peptide ends explained as “start” and “finish” are more than a memory trick. Direction is part of molecular identity. A label such as Ac-YADA...MSR-NH2 places an acetyl cap at the N end and an amide at the C end.

Read a written peptide in three passes:

1. Start with the leftmost amino-acid letter or three-letter code; that is residue 1 at the N-terminal end.
2. Move right through the chain in numerical order.
3. Finish at the C-terminal residue, then check for a suffix such as -NH2 that changes the end.

Prefixes matter too. Ac- commonly marks N-terminal acetylation. A plain sequence without terminal labels is usually understood as N to C, but a complete chemical description should state any caps. Two strings with the same amino acids can still describe different molecules if their direction or end chemistry differs. The sequence glossary covers the one-letter code itself; this page covers which way to read it.

Why do chemists modify peptide ends?

Chemists modify peptide ends because enzymes can grab an exposed end and trim amino acids away. N-terminal acetylation covers the amino end; an amidated C-terminus converts the usual carboxyl end to an amide. These caps can slow end-trimming enzymes and extend half-life, helping an analog outlast an uncapped parent.

Terminal modifications can also change electrical charge, shape, solubility, receptor binding, and biological activity. That is why an amidated C-terminus is part of the compound’s identity, not decorative punctuation after the sequence. An uncapped and capped version should not be treated as interchangeable merely because the letters between their ends match.

End caps mainly address exopeptidases—enzymes that work inward from an exposed end. Endopeptidases cut peptide bonds inside the chain. Covering the front and back doors does not stop someone using a window, chemically speaking, so designers may also replace internal amino acids, attach a fatty chain, or cyclize a peptide.

Does an end cap always make a peptide last longer?

An end cap does not always make a peptide last longer; the result depends on the sequence, the enzyme, and the biological setting. “Amidated” tells you what was changed, not the size of the half-life gain. A measured comparison is stronger evidence than assuming every capped analog behaves the same way.

A human-serum laboratory study makes the distinction unusually clear. N-terminal acetylation increased protease resistance in the short antimicrobial peptides tested, while C-terminal amidation made little difference to their degradation. Cyclization protected some peptides more strongly. Those are biochemical measurements in human serum, not outcomes from treating people.

The evidence tier here is therefore laboratory evidence. The chemistry explains why a capped analog can outlast an uncapped parent, but only pharmacokinetic testing—measuring how concentrations change over time—shows whether a particular modification actually extends half-life in an animal or person. That separation keeps a plausible design feature from quietly turning into a clinical claim.

What does an amidated C-terminus look like in a real peptide?

An amidated C-terminus is often written as -NH2, “amide,” or -CONH2 after the sequence. Sermorelin, a peptide in the growth-hormone family, is a carried example: its sequence is GHRH(1-29)-NH2, and PubChem lists the name somatotropin-releasing-hormone(1-29)amide.

Sermorelin also shows why the N/C labels matter in names. GHRH(1-29) identifies the first 29 residues—the N-terminal active fragment—of the longer natural growth hormone-releasing hormone. The trailing NH2 separately identifies the amidated C-terminus of that shortened peptide. One compact name therefore reports origin, length, direction, and end chemistry.

That suffix tells you the finish has been capped. Sermorelin’s existence does not prove that amidation alone explains its duration; sequence, internal cleavage sites, folding, dose, and route can matter too. Read -NH2 as a verified structural fact, then look for measured half-life evidence before making a stability claim.